Comparing of MediWound Ltd. (MDWD) and Spero Therapeutics Inc. (NASDAQ:SPRO)

MediWound Ltd. (NASDAQ:MDWD) and Spero Therapeutics Inc. (NASDAQ:SPRO), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation of the two firms.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MediWound Ltd. 2.94M 42.91 13.91M -0.51 0.00
Spero Therapeutics Inc. 3.27M 53.51 45.83M -3.06 0.00

Table 1 highlights MediWound Ltd. and Spero Therapeutics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 represents MediWound Ltd. (NASDAQ:MDWD) and Spero Therapeutics Inc. (NASDAQ:SPRO)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
MediWound Ltd. -473.13% -403.7% -35.9%
Spero Therapeutics Inc. -1,401.53% -52.4% -47.8%

Liquidity

The Current Ratio of MediWound Ltd. is 5.5 while its Quick Ratio stands at 5.2. The Current Ratio of rival Spero Therapeutics Inc. is 13 and its Quick Ratio is has 13. Spero Therapeutics Inc. is better equipped to clear short and long-term obligations than MediWound Ltd.

Analyst Recommendations

In next table is shown MediWound Ltd. and Spero Therapeutics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MediWound Ltd. 0 0 0 0.00
Spero Therapeutics Inc. 1 0 0 1.00

Spero Therapeutics Inc. on the other hand boasts of a $9 average price target and a -11.42% potential downside.

Institutional & Insider Ownership

The shares of both MediWound Ltd. and Spero Therapeutics Inc. are owned by institutional investors at 36.8% and 59.8% respectively. Insiders held 41.5% of MediWound Ltd. shares. Comparatively, 0.5% are Spero Therapeutics Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MediWound Ltd. -9.88% -10.19% -22.39% -21.8% 9.47% 16.85%
Spero Therapeutics Inc. -17.85% -22.13% -36.6% -41.77% -36.06% -42.81%

For the past year MediWound Ltd. has 16.85% stronger performance while Spero Therapeutics Inc. has -42.81% weaker performance.

Summary

MediWound Ltd. beats on 6 of the 11 factors Spero Therapeutics Inc.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.